Effect of Endobronchial Coils on Exercise Tolerance and Lung Functions in Patients with Severe Emphysema - A Retrospective Cohort Study of 48 Patients

• Published in: International journal of chronic obstructive pulmonary disease 2021-01, Vol.16, p.2809-2815
• Main Authors: Pertzov, Barak, Soliman, Maysaa, Shostak, Yael, Heching, Moshe, Rosengarten, Dror, Izbicki, Gabriel, Kramer, Mordechai Reuven
• Format: Article
• Language: English
• Subjects: Analysis; Bronchoscopy; Carbon monoxide; Care and treatment; Chronic obstructive pulmonary disease; Cohort analysis; Complications and side effects; Emphysema; Emphysema, Pulmonary; endobronchial coils; Endoscopy; Exercise Tolerance; fev1; Forced Expiratory Volume; Humans; Lung; lung volume reduction; Medical research; Medicine, Experimental; Original Research; Patients; Pneumonectomy; Pneumothorax; Pulmonary Disease, Chronic Obstructive - diagnosis; Pulmonary Disease, Chronic Obstructive - therapy; Pulmonary Emphysema - surgery; Pulmonary Emphysema - therapy; Pulmonary function tests; residual volume; Retrospective Studies; six-minute walk; Success; survival; Survival analysis; Transplants & implants; Treatment Outcome
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S327048

Lung volume reduction with endobronchial coils treatment (ECT), for patients with severe emphysema, has shown modest improvement in exercise capacity and lung functions in clinical trials, yet the benefit of this procedure is still unclear. We conducted a multicenter retrospective cohort study including all patients who underwent ECT in Israel and a propensity score matched control group of patients with chronic obstructive pulmonary disease (COPD) that were treated with usual care. The primary outcome was six-minute walk test distance (6MWTD), secondary outcomes were lung function tests and patient survival. Overall, 46 patients were included in the ECT group. Their mean 6MWTD at baseline and at 6 and at 24 months post procedure was 331.0±101.4, 372.9±76.8 and 338.8±104.8, respectively (overall P=0.04, pairwise comparison: baseline to 6 months (P=0.1), baseline to 24 months (P=1.0)). Mean FEV1 values at baseline and at 6 and at 24 months post procedure were 0.86±0.38, 0.92±0.37 and 0.82±0.36 liters, respectively (overall P=0.003, pairwise comparison: baseline to 6 months (P=0.04), baseline to 24 months (P=0.75)). The median 6MWTD for the ECT and control groups at 24 months were 333.0 (262.5-390) and 280 (210-405), respectively (P=0.16). There was no difference in overall survival (P=0.84). Heterogenous emphysema was a significant predictor of treatment success in univariate analysis (p=0.004). Lung volume reduction with endobronchial coils may improve the exercise capacity and FEV1 of COPD patients. However, the majority of the effect was diminished after 24 months. The current state of evidence does not support regulatory approval of ECT and warrant its use only after consideration of the benefit-harm ratio in a highly selected patient population.